Damon R. Race, President &
CEO
RALEIGH,
N.C., April 16, 2024 /PRNewswire/ -- GeneVentiv
Therapeutics, developer of GENV-HEM (AAV8.FVa) for all hemophilias,
announced today it has been awarded a Direct to Phase II Small
Business Innovation Research (SBIR) grant for approximately
$2,500,000 from the National Heart
Lung Blood Institute (NHLBI) at the National Institutes of Health
(NIH). The award for "Development of a universal gene therapy for
hemophilia A or B with or without inhibitors" enables a large
animal study and assay development to support IND-enabling
biodistribution and toxicology studies.
GENV-HEM is serotype 8 Adeno-associated virus (AAV) expressing
the active form of coagulation Factor V (FVa).
"GENV-HEM successfully treats hemophilia A or B with or without
inhibitors in mice. The NIH award funds the testing of GENV-HEM in
a canine model of hemophilia. The grant also supports assay
development for an IND-enabling biodistribution and toxicology
study to be funded by our Series A," commented Paris Margaritis, CSO of GeneVentiv
Therapeutics.
"Non-dilutive grant funding and our recent manufacturing
collaboration substantially address GENV-HEM production and assay
development costs, ensuring that investors' funds are maximally
allocated to value increasing IND-enabling studies," said
Damon Race, CEO of GeneVentiv
Therapeutics.
"GENV-HEM has the potential for lifetime treatment of hemophilia
patients with or without inhibitors with a single infusion. This
grant funding from NIH moves GENV-HEM one step closer to IND
submission."
About GeneVentiv Therapeutics:
GeneVentiv Therapeutics is a pre-clinical gene therapy company.
Our lead program, GENV-HEM (AAV8.FVa), is the only single infusion,
universal, AAV-based gene therapy able to treat all types of
hemophilia with or without inhibitors. There are approximately
150,000 hemophilia patients in the developed world. GENV-HEM has
received Orphan Drug Designation from the FDA for Hemophilia A and
B with or without inhibitors and a Letter of Support from the
National Bleeding Disorders Foundation. For additional information
about GeneVentiv, please visit www.geneventiv.com.
Media Contact:
Damon Race
(919) 529-3352
376006@email4pr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/geneventiv-therapeutics-awarded-2-5-million-sbir-grant-to-advance-gene-therapy-for-all-hemophilias-with-or-without-inhibitors-302116947.html
SOURCE GeneVentiv Therapeutics, Inc.